Background

• Rectal carcinoma refers to cancer that originates in the rectum, located just above the anus. It is a type of colorectal cancer, with the rectum serving as the last segment before stool is expelled from the body. Rectal carcinoma shares similarities with colon cancer but has distinct features in terms of anatomy, staging, and treatment. 
• The development of rectal carcinoma is often associated with a series of genetic mutations that lead to the uncontrolled growth of cells in the rectal lining. Risk factors for rectal carcinoma include age, family history of colorectal cancer, a history of polyps, inflammatory bowel disease, and lifestyle changes. 
• Early-stage rectal carcinoma may not present noticeable symptoms, but as disease progresses, individuals may experience the changes in bowel habits, abdominal pain, and unintentional weight loss. It typically involves a combination of imaging studies, endoscopic procedures like colonoscopy, and biopsy to confirm malignancy. 
• Treatment for rectal carcinoma is multifaceted and may include surgery, chemotherapy, and radiation therapy. The choice of treatment depends on the stage of cancer, its location within the rectum, and the overall health of the patient. Surgical options range from local excisions for early-stage tumors to more extensive procedures like total mesorectal excision for advanced cases. 
• Early detection through screenings and prompt medical intervention is crucial for a more favorable prognosis. Colorectal cancer screening guidelines recommend routine colonoscopies, especially for individuals with risk factors or those above a certain age. As with many cancers, ongoing research aims to enhance our understanding of rectal carcinoma, improve diagnostic methods, and develop more effective treatments. Patient education and awareness campaigns play a vital role in promoting early detection and encouraging individuals to seek medical attention for potential signs and symptoms. 

Epidemiology

• Incidence and Prevalence: Colorectal cancer, including rectal carcinoma, is one of the most common cancers globally. The incidence of rectal carcinoma varies across regions, with higher rates observed in developed countries. 
• Geographic Variation: There are geographic variations in the incidence of rectal carcinoma. Western countries, such as the United States and parts of Europe, report higher rates compared to some Asian and African nations. Lifestyle factors, including diet and physical activity, may contribute to these geographic differences. 
• Screening and Early Detection: The introduction of colorectal cancer screening programs, including colonoscopies and fecal occult blood tests, has contributed to the early detection of rectal carcinoma. Screening is recommended in individuals with risk factors or above a certain age, usually starting at 50 years. 
• Survival Rates: Survival rates for rectal carcinoma have improved over the years, particularly with advancements in early detection and treatment. Survival outcomes are influenced by the stage at diagnosis, with earlier stages generally associated with better prognoses. 
• Treatment Advances: Treatment modalities for rectal carcinoma have evolved, incorporating surgery, chemotherapy, and radiation therapy. Total mesorectal excision (TME) is a surgical technique that has become a standard for treating rectal cancer, especially in advanced cases. 

Anatomy

Pathophysiology

Etiology

• Hereditary Syndromes: Some individuals may have an increased risk of rectal carcinoma due to familial adenomatous polyposis (FAP) or Lynch syndrome. 
• Genetic Mutations: Specific genetic mutations, including alterations in the APC, KRAS, TP53, and other genes, can contribute to the development of colorectal cancer. 
• Family History: Having a family history of colorectal cancer increases an individual’s risk. The presence of multiple affected family members or cases diagnosed at a young age may suggest a hereditary component. 
• Personal History of Colorectal Polyps: Individuals with a history of adenomatous polyps in the colon or rectum are at an increased risk of developing rectal carcinoma. Adenomatous polyps may progress to cancer over time, following the adenoma-carcinoma sequence. 
• Inflammatory Bowel Disease (IBD): The individuals with ulcerative colitis or Crohn’s disease affecting the rectum, have an elevated risk of developing rectal carcinoma. Chronic inflammation may contribute to genetic mutations and the initiation of cancerous changes. 
• Diabetes: The individuals with type 2 diabetes may have an increased risk of colorectal cancer, including rectal carcinoma. 
• Radiation Exposure: Prolonged exposure to high levels of radiation, such as in certain medical treatments or occupational settings, may increase the risk of colorectal cancer. 
• Human Papillomavirus (HPV): While the primary association of HPV is with cervical cancer, some studies suggest a potential link between HPV infection and colorectal cancer, including rectal carcinoma. 

Genetics

Prognostic Factors

• Tumor Stage: The stage of the tumor, determined by the extent of its spread, is a critical prognostic factor. Staging is typically classified into stages I to IV, with higher stages indicating advanced disease. 
• Tumor Location: The specific location of the tumor within the rectum can influence the prognosis. Tumors in the upper rectum may have different outcomes compared to those in the lower rectum. 
• Tumor Size: Larger tumors often have a worse prognosis. Tumor size is usually measured in terms of its greatest dimension (in centimeters). 
• Histological Grade: The grade of the tumor, reflecting its cellular characteristics and degree of differentiation, is an important factor. Higher-grade tumors may be more aggressive and associated with a poorer prognosis. 
• Margins of Resection: The completeness of surgical resection, particularly the status of surgical margins (whether tumor-free or involved), is a significant prognostic factor. Negative margins indicate better outcomes. 
• Response to Neoadjuvant Therapy: The response of the tumor to neoadjuvant (preoperative) therapies, such as chemotherapy and radiation, can impact prognosis. A favorable response may improve the chances of successful surgery. 
• Microsatellite Instability (MSI): Tumors with microsatellite instability may have a better prognosis. MSI status is determined by genetic testing and has implications for treatment strategies. 
• KRAS and BRAF Mutations: Specific genetic mutations, such as KRAS and BRAF mutations, can influence the prognosis and response to certain treatments. 

Clinical History

• Age: Rectal carcinoma can affect individuals of various ages, but it is more commonly diagnosed in the age of 50. Younger individuals may be affected, especially if there is a strong family history of colorectal cancer or if they have a hereditary predisposition. 
• Associated Comorbidities: The presence of medical conditions or comorbidities can influence the overall management and prognosis of rectal carcinoma. Conditions such as diabetes, cardiovascular disease, or other chronic illnesses may impact treatment decisions and overall health. 
• Acuity of Presentation:The acuity of presentation can vary, and individuals may present with a range of symptoms. Some cases are identified during routine screenings, while others may present with more urgent and symptomatic conditions. Common symptoms including changes in bowel habits, rectal bleeding, abdominal pain or discomfort, unintended weight loss, and fatigue. The acuity of presentation may be influenced by factors like size & location of the tumor, the presence of obstruction, or the degree of anemia due to bleeding. 

Physical Examination

• General Inspection: The healthcare provider begins with a general inspection, assessing the patient’s overall appearance, vital signs, and signs of distress. 
• Abdominal Examination: Palpation of the abdomen is done to assess for tenderness, masses, or any signs of abdominal distension. The presence of abdominal mass may indicate the extent of the rectal carcinoma or potential involvement of adjacent structures. 
• Digital Rectal Examination (DRE): DRE is a crucial part of the examination. It involves insertion of a lubricated, gloved finger into the rectum to assess the rectal wall, the presence of tumors, and the proximity of the tumor to the anal verge. DRE allows for the evaluation of the size, shape, and mobility of the rectal mass. It may also provide information about the presence of blood in the stool. 
• Proctoscopy or Sigmoidoscopy: These procedures involve the use of a lighted tube with a camera (proctoscope or sigmoidoscope) to visually inspect the rectum and lower part of the colon. Proctoscopy or sigmoidoscopy provides a direct view of the rectal mucosa and any visible lesions, allowing for a more detailed assessment. 
• Colonoscopy: A full colonoscopy may be recommended to examine the entire colon and rectum, especially if a lesion or mass is detected during the initial examinations. Colonoscopy allows for the visualization of the entire colorectal mucosa and the performance of biopsies for definitive diagnosis. 
• Assessment of Lymph Nodes: Palpation of regional lymph nodes, such as inguinal and perirectal nodes, is performed to assess for enlargement, which may indicate metastasis. 
• Assessment of Anus and Perianal Area: Examination of the anus and perianal area is important for detecting abnormalities, such as fissures, hemorrhoids, or signs of local invasion. 
• Neurological Examination: It may be conducted to assess for any neurological deficits or symptoms related to nerve involvement. 
• Assessment of Performance Status: An evaluation of the patient’s performance status, including their ability to perform daily activities, is essential for treatment planning. 

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

• Hemorrhoids: These are the swollen blood vessels in rectum and anus that can cause bleeding, discomfort, and pain during bowel movements. They may be mistaken for rectal carcinoma, especially if bleeding is the primary symptom. 
• Anal Fissures: These are the small tears in the lining of anus, often causing pain and bleeding during bowel movements. They are a common cause of rectal bleeding and can be mistaken for more serious conditions. 
• Diverticulitis: The inflammation or infection of small pouches in the colon may cause symptoms similar to those of rectal carcinoma, including abdominal pain and changes in bowel habits. 
• Colorectal Polyps: Benign growths in the colon or rectum, known as polyps, can cause bleeding and may be detected during colorectal cancer screenings. Some polyps may have the potential to become cancerous. 
• Anal Cancer: Cancer that originates in the anal canal may present with symptoms similar to rectal carcinoma. Anal cancer is a distinct entity that requires specific diagnostic evaluation. 
• Infectious Colitis: Infections of the colon, such as bacterial or parasitic colitis, can cause symptoms resembling colorectal cancer. These infections may be associated with diarrhea, abdominal pain, and rectal bleeding. 
• Ischemic Colitis: A reduced blood flow to the colon can lead to ischemic colitis, which may present with symptoms like abdominal pain and bleeding. Ischemic colitis is more common in older adults with vascular risk factors. 
• Infectious Proctitis: Infections of the rectum, such as sexually transmitted infections (e.g., gonorrhea, chlamydia), can lead to proctitis, causing rectal pain and discharge. 
• Solitary Rectal Ulcer Syndrome: This rare condition involves the development of ulcers in the rectum, leading to symptoms like rectal bleeding, mucous discharge, and difficulty with bowel movements. 
• Endometriosis Involving the Rectum: In women, endometriosis can involve the rectum, causing pain, bleeding, and changes in bowel habits. 

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

• Local Excision: For early-stage tumors that are confined to the inner layers of the rectum, local excision may be considered. This can be done through techniques such as transanal excision. 
• Total Mesorectal Excision (TME): TME is a standard surgical procedure for more advanced tumors. It involves the removal of the rectum and surrounding tissues while preserving the anal sphincter function. The goal is to achieve clear margins and minimize the risk of recurrence. 

Neoadjuvant Therapy: 

• Chemotherapy: Neoadjuvant chemotherapy may be administered before surgery to shrink tumor and reduce the risk of recurrence. Commonly used chemotherapy drugs include fluorouracil (5-FU) and oxaliplatin. 
• Radiation Therapy: The Neoadjuvant radiation therapy is used especially for tumors located in the lower part of the rectum. It helps to reduce size of the tumor and improve the chances of successful surgery. 

Adjuvant Therapy: 

• Following surgery, adjuvant therapy may be recommended to eliminate remaining cancer cells and reduce recurrence. 

Targeted Therapy: 

• Targeted therapies, such as anti-EGFR (epidermal growth factor receptor) or anti-VEGF (vascular endothelial growth factor) medications, may be used in combination with chemotherapy for advanced cases with specific genetic markers. 

Immunotherapy: 

• Immunotherapy drugs, such as checkpoint inhibitors, may be considered in certain cases. Research is ongoing to explore the effectiveness of immunotherapy in colorectal cancer treatment. 

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

non-pharmacological-treatment-of-rectal-carcinoma

Lifestyle modifications: 

• Adopting a Healthy Diet: A diet including vegetables, fruits, whole grains & lean proteins. Limit the intake of processed meats, as it leads to increased risk of colorectal cancer. Adequate fiber intake can contribute to regular bowel movements and overall digestive health. 
• Maintaining a Healthy Weight: Strive for a healthy body weight through regular physical activity and balanced nutrition. Obesity has an increased risk of colorectal cancer, and maintaining the healthy weight can positively impact treatment outcomes. 
• Avoiding Smoking and Limiting Alcohol Intake: Quit smoking, as tobacco use may have an increased risk of colorectal cancer and can negatively impact overall health. Limit alcohol consumption, as excessive alcohol intake is associated with increased risk of colorectal cancer. 
• Regular Screening and Follow-Up: Adhere to recommended screening guidelines for colorectal cancer, as early detection may lead to more effective treatment. Attend regular follow-up appointments with healthcare providers for surveillance and monitoring. 
• Hydration: Stay hydrated by drinking sufficient quantity of water throughout the day. Proper hydration helps in overall health and can help manage potential side effects of treatments. 
• Patient Education: Be actively involved in understanding the diagnosis, treatment options, and potential side effects. Seek reliable sources of information, and communicate openly with healthcare providers about questions and concerns. 
• Social Support: Cultivate a strong support system, including friends, family, and support groups. Emotional well-being is an integral part of the overall health and healing process. 

use of Neoadjuvant Therapy in the treatment of Rectal Carcinoma

Neoadjuvant therapy is administered before surgery, is a common and effective approach in the treatment of rectal carcinoma. This strategy involves the use of chemotherapy and sometimes radiation therapy to shrink the tumor, reduces the risk of recurrence. Fluorouracil (5-FU) and oxaliplatin are two chemotherapy agents frequently used in neoadjuvant therapy for rectal carcinoma.  

Fluorouracil (5-FU): 

• Mechanism of Action: 5-FU is an antimetabolite that interferes with synthesis of DNA and RNA by inhibiting growth and division of cancer cells. 
• Administration: 5-FU is commonly administered intravenously, either as a continuous infusion or in bolus injections. 

Role in Neoadjuvant Therapy: 

• 5-FU is often used in combination with other chemotherapy agents, such as leucovorin or folinic acid, to enhance its effectiveness. 
• It is a key component of many neoadjuvant chemotherapy regimens for rectal carcinoma. 
• Neoadjuvant 5-FU helps reduce the size of the tumor, making it more amenable to surgical removal. 

Oxaliplatin: 

• Mechanism of Action: Oxaliplatin is a platinum-based chemotherapy agent that forms DNA adducts, disrupting DNA replication and leading to cell death. 
• Administration: Oxaliplatin is typically administered intravenously in combination with other chemotherapy agents. 

Role in Neoadjuvant Therapy: 

• Oxaliplatin is used in combination with 5-FU and leucovorin in neoadjuvant chemotherapy regimens for rectal carcinoma. 
• It adds to the efficacy of the treatment, particularly in more advanced cases. 
• The combination of 5-FU and oxaliplatin is commonly referred to as FOLFOX (5-FU, leucovorin, and oxaliplatin) and is used in both neoadjuvant and adjuvant settings. 

use of Adjuvant Therapy in the treatment of Rectal Carcinoma

Adjuvant therapy is a crucial component in the treatment of rectal carcinoma, especially after surgical removal of the tumor. This postoperative treatment is designed to eliminate any residual cancer cells, reduce the risk of local recurrence, and improve overall survival. Fluorouracil (5-FU), capecitabine, or a combination of drugs are commonly used in adjuvant therapy for rectal carcinoma.  

Fluorouracil (5-FU): 

• 5-FU is an antimetabolite that interferes with synthesis of DNA and RNA, inhibiting the growth and division of cancer cells. 
• Administration: 5-FU is typically administered intravenously, either as a continuous infusion or in bolus injections. 

Role in Adjuvant Therapy: 

• 5-FU has been a cornerstone of adjuvant therapy for colorectal cancer, including rectal carcinoma. 
• It is often used in combination with leucovorin or folinic acid to enhance its effectiveness. 
• The combination of 5-FU and leucovorin is known as the Mayo Clinic regimen and is one of the standard adjuvant chemotherapy regimens. 

Capecitabine: 

• Mechanism of Action: Capecitabine is an oral prodrug of 5-FU. It is converted to 5-FU in the body, allowing for convenient oral administration. 
• Administration: Capecitabine is taken orally and is converted to 5-FU in the body. 

Role in Adjuvant Therapy: 

• Capecitabine is often used as an alternative to intravenous 5-FU in adjuvant therapy for rectal carcinoma. 
• It is particularly convenient for patients who prefer oral medications and can be an effective substitute for 5-FU in various chemotherapy regimens. 

Combination Therapy: 

• FOLFOX (5-FU, Leucovorin, Oxaliplatin): In some cases, adjuvant chemotherapy may include a combination of 5-FU, leucovorin, and oxaliplatin (FOLFOX regimen). This combination has demonstrated efficacy in colorectal cancer, including rectal carcinoma. 
• XELOX (Capecitabine, Oxaliplatin): Another combination, known as XELOX, involves the use of capecitabine and oxaliplatin. 

use of Biologic therapy in the treatment of Rectal Carcinoma

Biologic therapies, also known as targeted therapies, play a role in the treatment of rectal carcinoma, particularly in cases with specific genetic or molecular characteristics. These therapies are designed to target molecules involved in growth and survival of cancer cells. 

Cetuximab and Panitumumab: 

• Mechanism of Action: 
• Cetuximab: It is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). EGFR is often overexpressed in colorectal cancer cells, promoting their growth. 
• Panitumumab: Similar to cetuximab, panitumumab is a monoclonal antibody that specifically targets EGFR. 
• Clinical Use: 
• Cetuximab and panitumumab are used in metastatic colorectal cancer, including rectal carcinoma. 
• They are often employed in combination with chemotherapy, such as FOLFOX (5-FU, leucovorin, oxaliplatin) or FOLFIRI (5-FU, leucovorin, irinotecan). 

Pembrolizumab: 

• Mechanism of Action: 
• Pembrolizumab targets programmed cell death protein 1 (PD-1) receptor. It enhances the immune system’s ability to recognize and attack cancer cells. 
• Clinical Use: 
• Pembrolizumab may be used in the treatment of metastatic colorectal cancer with specific genetic features, such as high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). 
• It is typically considered in cases where conventional treatments, including chemotherapy, have not been effective. 

Fruquintinib (Fruquintinib): 

• Mechanism of Action: 
• Fruquintinib is an oral small molecule inhibitor that targets vascular endothelial growth factor receptors (VEGFRs). 

• It inhibits angiogenesis that supply nutrients to the tumor. 
• Clinical Use: 
• Fruquintinib is approved for the treatment of metastatic colorectal cancer in patients with previously received chemotherapy. 
• It is often considered when other treatment options, including chemotherapy, have been exhausted. 

use of Radiation Therapy in the treatment of Rectal Carcinoma

Neoadjuvant Radiation Therapy: 

• Purpose: Neoadjuvant radiation therapy is administered before surgery with the goal of reducing the size of the tumor, making it more amenable to surgical removal, and improving the chances of sphincter preservation. 
• Treatment Planning: Radiation therapy is carefully planned to target the tumor and surrounding tissues while minimizing exposure to nearby healthy structures. 
• Common Techniques: External beam radiation therapy (EBRT) is the most common technique, where a machine delivers targeted radiation to the tumor from outside the body. Intensity-modulated radiation therapy (IMRT) is a specialized form of EBRT that allows for precise dose adjustments. 
• Combined with Chemotherapy: Neoadjuvant radiation therapy is often combined with chemotherapy (neoadjuvant chemoradiotherapy or nCRT) to enhance its effectiveness. 

Adjuvant Radiation Therapy: 

• Purpose: Adjuvant radiation therapy is given after surgical removal of the tumor. Its primary objectives include eliminating any remaining cancer cells, reducing the risk of recurrence. 
• Indications: Adjuvant radiation therapy is typically considered for patients with certain high-risk features, such as involvement of nearby lymph nodes, positive margins, or extramural vascular invasion. 
• Treatment Planning: Similar to neoadjuvant radiation therapy, adjuvant radiation therapy is carefully planned to target the surgical bed and areas at risk of recurrence. 
• Postoperative Timing: Adjuvant radiation therapy is usually initiated a few weeks after surgery to allow for initial wound healing. 

use-of-transanal-excision-in-the-treatment-of-rectal-carcinoma

Transanal excision is a surgical procedure used in the treatment of early-stage rectal carcinoma. It is a minimally invasive approach that is particularly suitable for small and superficial tumors located in the lower part of the rectum. Here’s an overview of the use of transanal excision in the treatment of rectal carcinoma: 

• Indications: Transanal excision is typically considered for early-stage rectal carcinomas that are limited to the inner layers of the rectal wall. It is particularly suitable for tumors that are small, well-differentiated, and located in the lower rectum. 
• Local Approach: Transanal excision is performed locally through the anus, eliminating the need for a formal abdominal incision. 
• Endoscopic or Transanal Techniques: The procedure can be carried out using endoscopic or transanal techniques, often with specialized instruments and equipment. 
• Complete Excision: The goal is to completely excise the tumor with healthy tissue to ensure that no cancer cells are left. 
• Sphincter Preservation: Transanal excision is associated with the preservation of sphincter function, as it avoids the need for more extensive surgeries that may involve removing a portion of the rectum and creating a permanent colostomy. 
• Preoperative Assessment: Prior to transanal excision, a thorough preoperative assessment is conducted to determine the size and extent of the tumor, as well as its suitability for this localized approach. Imaging studies such as endorectal ultrasound or magnetic resonance imaging may be used to assess tumor characteristics. 

use-of-transanal-endoscopic-microsurgery-tem-in-the-treatment-of-rectal-carcinoma

Transanal Endoscopic Microsurgery (TEM) is a surgical technique used in the treatment of rectal carcinoma, particularly for early-stage tumors. It is the minimally invasive procedure that allows for the removal of lesions or tumors located in the rectum with the use of an endoscope and microsurgical instruments. Here’s an overview of the use of Transanal Endoscopic Microsurgery in the treatment of rectal carcinoma: 

Indications: 

• Early-Stage Tumors: TEM is most suitable for early-stage rectal carcinomas that are limited to the inner layers of the rectal wall. 
• Benign Lesions: It can also be used for the removal of benign rectal lesions, such as adenomas. 

Procedure: 

• Minimally Invasive: TEM is a minimally invasive procedure that is performed through the anus without the need for a formal abdominal incision. 
• Endoscopic Visualization: The surgeon uses an endoscope with a high-resolution camera to visualize the rectal area and magnify the view. 
• Microsurgical Instruments: Specialized microsurgical instruments are used to excise the tumor or lesion with precision. 

Complete Excision: 

• The goal of TEM is to achieve complete excision of tumor along with a margin of healthy tissue, ensuring no cancer cells are left behind. 
• The excised tissue is then carefully evaluated by pathologists to determine the extent of the tumor and the adequacy of the resection. 

Sphincter Preservation: 

• TEM is associated with the preservation of sphincter function, as it allows for the removal of tumors while avoiding more extensive surgeries that might involve the removal of a portion of the rectum and creation of a permanent colostomy. 

use-of-sphincter-sparing-procedures-in-the-treatment-of-rectal-carcinoma

Sphincter-sparing procedures are surgical techniques designed to preserve the anal sphincter and maintain normal bowel function in the treatment of rectal carcinoma. The aim is to avoid a permanent colostomy and allow patients to maintain continence. Several sphincter-sparing procedures are utilized, depending on the location and extent of the tumor. Here are some common sphincter-sparing procedures in the treatment of rectal carcinoma: 

Total Mesorectal Excision (TME): 

• Indications: TME is often employed for more advanced rectal carcinomas, especially those involving the middle or upper rectum. 
• Procedure: TME involves the removal of the entire mesorectum, the tissue surrounding the rectum that may contain lymph nodes. 
• Sphincter Preservation: While TME is not a local excision technique, it still aims to preserve the anal sphincter by carefully dissecting and removing the rectum while leaving the sphincter intact. 

Coloanal Anastomosis: 

• Indications: Coloanal anastomosis is considered when the tumor is located very low in the rectum, close to the anus. 
• Procedure: After removing the tumor, the surgeon creates an anastomosis between the remaining rectum and the anal canal. 
• Sphincter Preservation: This procedure preserves the anal sphincter and allows for the restoration of bowel continuity. 

Coloplasty: 

• Indications: Coloplasty is used in conjunction with coloanal anastomosis to address the issue of a dilated rectal reservoir. 
• Procedure: The rectal reservoir is narrowed and reshaped to improve function. 
• Sphincter Preservation: Coloplasty contributes to sphincter preservation and can enhance postoperative continence. 

management-of-rectal-carcinoma

Acute Phase: 

Diagnosis: 

• Clinical Evaluation: Initial assessment includes a thorough medical history, physical examination, and often colonoscopy for visualization of the rectum and biopsy. 

Neoadjuvant Therapy: 

• Chemoradiotherapy: Neoadjuvant chemoradiotherapy (chemotherapy combined with radiation therapy) may be administered before surgery and improve surgical outcomes. 
• Chemotherapy Alone: In some cases, neoadjuvant chemotherapy alone may be considered, especially for tumors with specific molecular characteristics. 

Surgery: 

• Total Mesorectal Excision (TME): Surgical resection of the rectal tumor is often performed, and TME is a common approach to ensure complete removal. 
• Sphincter-Sparing Procedures: Depending on tumor location, sphincter-sparing procedures like coloanal anastomosis or transanal excision may be considered to preserve bowel function. 

Adjuvant Therapy: 

• Chemotherapy: Adjuvant chemotherapy may be recommended based on the pathological findings post-surgery, especially for individuals with higher-risk features. 
• Radiation Therapy: Adjuvant radiation therapy may be considered for certain cases, such as those with positive margins or lymph node involvement. 

Chronic Phase: 

Postoperative Monitoring: 

• Regular Follow-Up: Patients undergo regular follow-up appointments to monitor for recurrence, assess treatment-related side effects, and address any new symptoms. 
• Imaging Studies: Periodic imaging studies, such as CT scans or MRIs, may be performed to monitor for any signs of recurrence. 

Maintenance Chemotherapy: 

• Ongoing Chemotherapy: For some individuals with advanced or metastatic disease, maintenance or palliative chemotherapy may be recommended to control the disease and manage symptoms. 

Rehabilitation and Survivorship: 

• Physical Therapy: Rehabilitation programs may be recommended to address physical challenges, particularly for individuals who have undergone sphincter-sparing procedures. 
• Psychosocial Support: Survivorship programs provide psychosocial support, addressing the emotional and social aspects of recovery. 

Long-Term Surveillance: 

• Colonoscopies: Long-term surveillance includes regular colonoscopies to monitor for any signs of new polyps or secondary cancers. 
• Lifestyle Modification: Encouraging and supporting healthy lifestyle choices, including diet and exercise, is essential for long-term well-being. 

Medication

Future Trends

Media Gallary

References

• Rectal cancer: a review – PMC 
• Rectal Cancer – StatPearls